Table 3.
Estimated number of HPV-attributable cancer deaths in the United States in 2017 and estimated YPLL associated with HPV-attributable cancer stratified by sex and HPV type.
| Total | Women | Men | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cervix | Vagina | Vulva | Anus | Oropharynx | Penis | Anus | Oropharynx | ||
| Estimated deathsa | |||||||||
| Any HPV | 7,085 | 3,812 | 308 | 868 | 677 | 182 | 223 | 388 | 628 |
| High-risk HPV types targeted by 9vHPVb | 6,482 | 3,403 | 302 | 793 | 661 | 173 | 200 | 362 | 588 |
| Estimated YPLL | |||||||||
| Any HPV | 154,954 | 100,998 | 4,405 | 12,247 | 12,548 | 3,249 | 3,377 | 7,223 | 10,905 |
| High-risk HPV types targeted by 9vHPVb | 141,019 | 90,185 | 4,311 | 11,179 | 12,249 | 3,095 | 3,036 | 6,751 | 10,212 |
| Estimated YPLL per death | 22 | 26 | 14 | 14 | 19 | 18 | 15 | 19 | 17 |
9vHPV, nonavalent HPV vaccine; HPV, human papillomavirus; YPLL, years of potential life lost.
a
HPV-attributable cancer deaths were calculated based on CDC WONDER-reported total US cancer deaths per type in 2017 (i.e., 4,207 cervical; 1,262 vulvar; 411 vaginal; 352 penile; 1,169 anal; 1,154 oropharyngeal).
b
HPV 16, 18, 31, 33, 45, 52, and 58.